SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

被引：4
|
作者：
Yu, Y. [1 ]
Yang, N. [2 ]
Zhang, Y. [3 ]
Zhang, H. [4 ]
Li, M. [5 ,16 ]
Yu, Q. [6 ]
Zhou, J. [7 ]
Hu, X. [8 ]
Fang, J. [9 ]
Zhao, H. [10 ]
Feng, J. [11 ]
Li, L. [12 ]
Shu, Y. [13 ]
Wang, X. [14 ]
Sun, M. [15 ]
Zhang, J. [15 ]
Li, M. [5 ,16 ]
Ren, Y. [15 ]
Lu, S. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Hunan Canc Hosp, Pulm Gastroenterol, Changsha, Peoples R China
[3] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Peoples R China
[4] Guangdong Prov Hosp Chinese Med, Dept Internal Med 1, Guangzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[6] Guangxi Med Univ, Affiliated Tumor Hosp, Resp Oncol Dept, Nanning, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Resp Med Dept, Hangzhou, Peoples R China
[8] Henan Tumor Hosp, Med Oncol, Zhengzhou, Peoples R China
[9] Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[10] Anhui Med Univ, Hosp 2, Dept Pneumol, Hefei, Peoples R China
[11] Nantong Univ, Affiliated Hosp, Dept Resp & Crit Care Med, Nantong, Peoples R China
[12] Sichuan Univ, West China Hosp, Resp Dept, Lung Canc Ctr, Chengdu, Peoples R China
[13] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[15] Haihe Biopharma Co Ltd, CSSD, Shanghai, Peoples R China
[16] Haihe Biopharma Co Ltd, BDS, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305MO
引用
收藏
页码：S1553 / S1553
页数：1
相关论文
共 50 条
  • [31] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [32] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
  • [33] Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
    Wang, Kaiwen
    Du, Robyn
    Roy-Chowdhuri, Sinchita
    Li, Ziping T.
    Hong, Lingzhi
    Vokes, Natalie
    Elamin, Yasir Y.
    Hume, Celyne Bueno
    Skoulidis, Ferdinandos
    Gay, Carl M.
    Blumenschein, George
    Fossella, Frank V.
    Tsao, Anne
    Zhang, Jianjun
    Karachaliou, Niki
    O'Brate, Aurora
    Gann, Claudia-Nanette
    Lewis, Jeff
    Rinsurongkawong, Waree
    Lee, J. Jack
    Gibbons, Don Lynn
    Vaporciyan, Ara A.
    Heymach, John V.
    Altan, Mehmet
    Le, Xiuning
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
  • [34] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [35] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [36] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [37] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.
    Li, J.
    Wang, J.
    Yang, L.
    Fang, J.
    Dong, X.
    Yi, T.
    Min, X.
    Xu, F.
    Chen, J.
    Zhong, D.
    Bai, J.
    Liu, L.
    Zeng, A.
    Tang, J.
    Wu, H.
    Luo, X.
    Yu, J.
    Su, W.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
  • [38] Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
    Ren, Xiaolin
    Li, Kejie
    Zhang, Yang
    Zou, Changlin
    Su, Meng
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Kuang, Linwu
    Zhang, Yuchen
    Wang, Hao
    Wang, Peng
    Li, Yangkai
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [40] Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
    Thanasombunsukh, K.
    Chamnongprasatporn, B.
    Chiravirakul, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S649 - S650
12345